Artemisinin-napthoquine versus dihydroartemisinin-piperaquine in adult subjects with Plasmodium vivax infection

Armedy Ronny Hasugian, Hadjar Siswantoro, Michael P. Fay, Emiliana Tjitra

Abstract


Abstrak

Latar belakang: Penelitian ini untuk membandingkan efikasi dan keamanan Artemisinin-Napthoquine(AN) dengan dosis tunggal dan obat pilihan ACT lain, dengan Dihydroartemisinin-Piperaquine (DHP)pada pengobatan P.vivax.

Metode: Penelitian ini adalah studi randomisasi terbuka dengan subyek direkrut mulai tahun 2007 – 2008dari RS St Gabriel, Maumere dan RS Polisi, RS Angkatan Darat dan RS Angkatan Laut di Jayapura.Penelitian ini merupakan bagian dari penelitian utama yang sudah dipublikasi sebelumnya. Efikasidinyatakan dengan ketiadaan klinis dan parasit malaria sampai dengan hari ke 42, disebut AdequateClinical and Parasitological Response (ACPR). Keamanan dinyatakan sebagai kejadian sampingan yangditemukan pada setiap kunjungan ulang yang tidak dilaporkan sebelumnya pada hari rekrutmen (h0).

Hasil: Total 158 subyek dianalisis. Sejumlah 80 subyek direkrut pada kelompok AN dan 78 dengan DHP.Median Parasite Clearance Estimator (PCE) yaitu 2,32 (kisaran: 1,42 – 7,78; IQR: 1,99 – 2,82) jam padaAN dan 2,05 (kisaran: 1,30 – 8,30; IQR: 1,82 – 2,46) jam pada DHP. Parasite clearance sudah terjadi dalam64 jam. Adequate clinical parasitological response (ACPR) at day 42 was 100% (95% CI: 95,2-100) padaAN, dan 100% (95% CI: 94,9-100) pada DHP. Kejadian Sampingan ditemukan ringan dan dapat ditoleransi.

Kesimpulan: Kedua obat memiliki efikasi dan keamanan yang sebanding untuk pengobatan malaria vivaksdewasa. Walaupun pembersihan parasit AN lebih lama dibandingkan DHP, 100% pembersihan terjadipada kedua kelompok pengobatan dalam 64 jam. (Health Science Journal of Indonesia 2015;6:92-8)

Kata kunci: malaria, Artemisinin, napthoquine ,dihydroartemisinin, vivax

 

Abstract

Background: This study was to compare the efficacy and safety between Artemisinin-Napthoquine (AN)as a single dose as well as an alternative drug, and Dihydroartemisinin-Piperaquine (DHP) as a three-daystandard regimen on P. vivax infection.

Methods: This was an open randomized study performed during the period of April 2007- March 2008 inthree Armed Forces Hospitals in Jayapura, Papua Province, and one private hospital in Maumere, East NusaTenggara Province. This study was a part from previously published study for any malaria infection. Efficacywas the absence of clinical and parasitological malaria until day 42, performed as Adequate Clinical andParasitological Response (ACPR). Safety was performed based on adverse event in any day of follow upwhich never reported at day recruitment (d0).

Results: This study analyses 158 P. vivax cases. A total 80 subjects were treated with AN and 78 with DHP.The median Parasite Clearance Estimator (PCE) was 2.32 (range: 1.42 – 7.78; Interquartile Range (IQR): 1.99– 2.82) hours in AN and 2.05 (range: 1.30 – 8.30; IQR: 1.82 – 2.46) hours in DHP group. The parasite clearancewas complete by 64 hours. The ACPR was 100% (95% Confidance Interval (CI): 95.2-100) in the AN, and100% (95% CI: 94.9-100) in the DHP group. Both drugs have similar mild and tolerated adverse events.

Conclusions: Both drugs have similar efficacy and safety for the treatment of P. vivax in adults. AlthoughAN has took longer PCE compared to DHP, 100% clearance was achieved in both groups in 64 hours.(Health Science Journal of Indonesia 2015;6:92-8)

Key word: malaria, Artemisinin, napthoquine ,dihydroartemisinin, vivax


References


World Malaria Report. Geneva: World Health Organization; 2013.

Gething PW, Elyazar IR, Moyes CL, et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS neglected tropical diseases. 2012;6:e1814. Epub 2012/09/13.

Tjitra E, Anstey NM, Sugiarto P, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua. Indonesia. PLoS Medicine. 2008;5:e128. Epub 2008/06/20.

Health Profile Indonesia. Jakarta: Departement of Health Republic of Indonesia; 2007. Indonesian.

Hasugian AR, Purba HL, Kenangalem E, et al. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007;44:1067-74. Epub 2007/03/17.

Health Data Profile Indonesia. Jakarta: CDC. Ministry of Health Republic of Indonesia; 2011. Indonesian.

Bloland PB. Drug resistance malaria. World Health Organization. 2001.

Congpuong K, Bualombai P, Banmairuroi V, et al. Compliance with a three-day course of artesunate-mefloquine combination and baseline anti-malarial treatment in an area of Thailand with highly multidrug resistant falciparum malaria. Malaria journal. 2010;9:43. Epub 2010/02/06.

Thanh NX, Trung TN, Phong NC, et al. The efficacy and tolerability of artemisinin-piperaquine (Artequick(R)) versus artesunate-amodiaquine (Coarsucam) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam. Malaria journal. 2012;11:217. Epub 2012/06/30.

Yeka A, Tibenderana J, Achan J, et al. Talisuna AO. Efficacy of quinine. artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children. PloS one. 2013;8(1):e53772. Epub 2013/01/26.

Hombhanje FW, Linge D, Saweri A, et al. Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy. Malaria journal. 2009;8:196. Epub 2009/08/13.

Wang J-y, Cao W-c, Shan C-q, et al. Naphthoquine phosphate and its combination with artemisinine. Acta Trop. 2004;89:375-81.

Guidelines treatment of malaria cases in Indonesia. Jakarta: General Directorat of Communicable Disease and Environment Health. Ministry of Health Republic of Indonesia; 2009.

Guideline Treatment of Malaria. Second Edition. . World Health Organization 2010. 2010.

Tjitra E, Hasugian AR, Siswantoro H, et al. Efficacy and safety of artemisinin-naphthoquine versus dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in Indonesia. Malaria journal. 2012;11:153. Epub 2012/05/05.

Ratcliff A,Siswantoro H, Kenangalem E, . Wuwung M. Brockman A. Edstein MD. et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua. Indonesia. Transactions of the Royal Society of Tropical Medicine and Hygiene. 2007;101:351-9. Epub 2006/10/10.

Tjitra E. Improving the diagnosis and treatment of malaria in eastern Indonesia. Darwin. Australia: Northern Territory University; 2001.

Methods for surveillance of antimalarial drug efficacy. World Health Organization. 2009.

Parasite Clearance Estimator [cited 2014 Dec 14]. Available from: https://www.wwarn.org/research/parasite-clearance-estimator.

Fay MP. Brittain EH. Proschan MA. Pointwise confidence intervals for a survival distributionwith small samples or heavy censoring. Biostatistics. 2013;14:723-36. Epub 2013/05/02.

Douglas NM, Anstey NM, Angus BJ, et al. Artemisinin combination therapy for vivax malaria. The Lancet Infectious Diseases. 2010;10:405-16.

Price RN, Douglas NM, Anstey NM, et al. Plasmodium vivax treatments: what are we looking for? Current opinion in infectious diseases. 2011;24:578-85. Epub 2011/10/12.

Wernsdorfer WH, Wernsdorfer G, Prajakwong S, et al. Activity correlation between artemisinin and dihydroartemisinin in fresh isolates of Plasmodium falciparum from Thailand. Tropenmed Parasitol. 2000;22:87-94.

Trung TN, Van Phuc D. A randomized. controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria. Chinese journal of integrative medicine. 2009;15:189-92.


Full Text: PDF

Refbacks

  • There are currently no refbacks.


---

Health Science Journal of Indonesia

p-ISSN: 2087-7021
e-EISSN: 2338-3437

Published by : Badan Litbang Kesehatan, Kementerian Kesehatan RI

Visitor of HSJI: View HSJI Stats


Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

 

Health Science Journal of Indonesia has been indexed by :